|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Modulates Ischemia Reperfusion Injury in the Heart
1 Surgery, Columbia University Medical Center, New York, New York, United States
2 Surgery, Columbia University, New York, New York, United States
3 Pathology, Columbia University Medical Center, New York, New York, United States
4 Medicine, Columbia University Medical Center, United States
5 Nephrology, Hannover Medical School, Hannover, Germany
* To whom correspondence should be addressed. E-mail: sy18{at}columbia.edu.
Protein kinase C
II (PKC
II) is an important modulator of cellular stress responses. To test the hypothesis that PKC
II modulates the response to myocardial ischemia/reperfusion (I/R) injury, we performed occlusion and reperfusion of the left anterior descending coronary artery (LAD) in mice. Homozygous PKC
null (-/-) or wild type mice fed the PKC
inhibitor, ruboxistaurin, displayed significantly decreased infarct size and enhanced recovery of left ventricular function; and reduced markers of cellular necrosis, serum CPK and LDH levels, compared to wild-type or vehicle-treated animals after 30 minutes of ischemia followed by 48 hours of reperfusion. Our studies revealed that membrane translocation of the PKC
II isoform in left ventricule tissue was sustained after I/R and that gene deletion or pharmacological blockade of PKC
protected ischemic myocardium. Homozygous deletion of PKC
significantly diminished phosphorylation of c-Jun NH2-terminal mitogen activated protein kinase (JNK MAPK) and expression of activated caspase 3 in left ventricle tissue of mice subjected to I/R. These data implicate PKC
in I/R-mediated myocardial injury, at least in part via phosphorylation of JNK, and suggest that blockade of PKC
may represent a potent strategy to protect the vulnerable myocardium.
This article has been cited by other articles:
![]() |
S. Bohl, D. J. Medway, J. Schulz-Menger, J. E. Schneider, S. Neubauer, and C. A. Lygate Refined approach for quantification of in vivo ischemia-reperfusion injury in the mouse heart Am J Physiol Heart Circ Physiol, December 1, 2009; 297(6): H2054 - H2058. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Liu, X. Chen, S. M. MacDonnell, E. G. Kranias, J. N. Lorenz, M. Leitges, S. R. Houser, and J. D. Molkentin Protein Kinase C{alpha}, but Not PKC{beta} or PKC{gamma}, Regulates Contractility and Heart Failure Susceptibility: Implications for Ruboxistaurin as a Novel Therapeutic Approach Circ. Res., July 17, 2009; 105(2): 194 - 200. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. G. Edwards, M. Y. White, and S. J. Cordwell The Role of Proteomics in Clinical Cardiovascular Biomarker Discovery Mol. Cell. Proteomics, October 1, 2008; 7(10): 1824 - 1837. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |